Presspart Manufacturing Limited

Presspart Manufacturing Limited specializes in the production of drug delivery devices, focusing on Metered-Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs) to enhance effective medication delivery for respiratory patients. Presspart Manufacturing Limited, founded in 1970, operates primarily in the UK and specializes in manufacturing drug delivery solutions. In 2002, the company was acquired by Heitkamp & Thurmann KG and rebranded as H&T Presspart. The company has a global presence with operations across Europe, North America, and Asia, serving a diverse clientele in the pharmaceutical sector.

H&T Presspart specializes in the manufacturing of drug delivery devices and pharmaceutical components. Its primary products include Metered-Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs), designed to enhance drug delivery efficiency. The company collaborates with leading pharmaceutical firms, providing essential components for their products, leveraging over 50 years of industry experience. In 2023, H&T Presspart reported a revenue of USD 60.

90 mn and an EBITDA of USD 17. 19 mn, primarily generated through B2B transactions with pharmaceutical companies. Revenue is derived from long-term contracts and volume-based pricing models for their flagship products, including the Vytal® RTU snap-fit closure technology. H&T Presspart's strategy for future growth includes the design and launch of new drug delivery products, with exact release dates to be confirmed.

The company aims to expand into additional markets in Asia and North America by 2025. Recent funding, raised during the acquisition in 2002, will support these initiatives by enhancing manufacturing capabilities and product development.